La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Vivani Medical a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Vivani Medical..

Vivani Medical (NASDAQ:VANI) Azioni, Catena delle Opzioni

Vivani Medical

Vivani Medical Inc is a preclinical-stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division.

Biotech

News

Health Care

Market-Moving Exclusives

Exclusives

General

VANI

L&#39;impianto GLP-1 di Vivani Medical riduce drasticamente l&#39;82% del grasso epatico: risultati preclinici promettenti per l&#39;obesità.

L&#39;impianto di Vivani riduce drasticamente il grasso epatico

Long Ideas

Penny Stocks

Markets

Trading Ideas

CYAN

Le recenti transazioni degli insider su Cyanotech, RENN Fund e Vivani Medical indicano fiducia nel mercato delle penny stock.

Penny stock: gli insider muovono il mercato con acquisti strategici

Vivani Medical Inc

Vivani Medical Inc Warrants (14/03/2024)

Vanilla Network

Qudian (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QD#NYSE">QD</a>) reported quarterly earnings of $0.10 per share. This is a 190.91 percent increase over losses of $(0.11) per share from the same period last year. The company reported $7.80 million in sales this quarter. This is a 92.26 percent increase over sales of $4.06 million the same period last year.

Earnings

Qudian Q3 Adj. EPADS $0.10 Up From $(0.11) YoY, Sales $7.80M Up From $4.06M YoY

JMP Securities analyst Matthew Carletti downgrades Root (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) from Market Outperform to Market Perform.

Downgrades

Analyst Ratings

ROOT

JMP Securities Downgrades Root to Market Perform

Texas Governor&nbsp;Greg Abbott (R-Texas) has directed state agencies to cease investments in China and divest existing ones. This decision, announced in a letter dated Nov. 21, highlights security and financial risks associated with Chinese investments, 
What Happened: Abbott&#8217;s directive argues that this aggression could elevate the financial risks tied to Chinese investments. The governor&#8217;s letter explicitly bans Texas investing entities from making new investments in China.
Moreover, Abbott has instructed these entities to divest from any current Chinese investments at the earliest feasible opportunity. 
&#8220;Texas will defend and safeguard itself and our public treasury from any potential threat, including those posed by the CCP,&#8221; the statement read.
See Also:&nbsp;<a href="https://www.benzinga.com/24/11/42103633/chinese-court-affirms-cryptocurrency-ownership-as-legal-as-bitcoin-breaks-97k?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Chinese Judge Cites &#8216;High-Pressure Crackdown&#8217; On Speculation In Judgment Declaring Crypto Ownership Legal As Bitcoin Moves Past $97K</a>
Why It Matters: The directive from Governor Abbott comes amid escalating U.S.-China tensions. Recently, the U.S. House of Representatives advanced two Republican bills aiming to reinstate the U.S. Justice Department's "China Initiative." This initiative seeks to <a href="https://www.benzinga.com/news/24/09/40831428/house-gop-advances-bills-to-reinstate-justice-departments-china-initiative-despite-white-house-disap">curb espionage activities</a> targeting U.S. intellectual property and academic institutions. The bills were part of the House Republican's &#8220;China Week,&#8221; which saw over two dozen China-related legislative measures passed.
President-elect Donald Trump has proposed to impose 60% tariff on Chinese goods. Chinese President Xi Jinping recently <a href="https://www.benzinga.com/24/11/42025284/xi-jinping-tells-joe-biden-china-is-ready-to-work-with-trump-as-tariff-threat-looms">expressed a willingness</a> to collaborate with the U.S. government, regardless of the administration in power. This statement was made during a meeting with President Joe Biden at the Asia-Pacific Economic Cooperation forum in Lima. 
Meanwhile, ETFs that allow investment into China have dropped during the past one month. As of Nov. 22nd, according to <a href="https://pro.benzinga.com">Benzinga Pro</a>, the KraneShares CSI China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>) has dropped by 5.97% while iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>) fell by 5.13%. Invesco Golden Dragon China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGJ#NASDAQ">PGJ</a>) fell by 5.41% and iShares MSCI China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHI#NASDAQ">MCHI</a>) dropped by 5.54%.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42111283/elon-musks-starlink-faces-new-competition-as-chinese-satellite-firm-spacesail-enters-brazilian-market?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s Starlink Faces New Competition As Chinese Satellite Firm Spacesail Enters Brazilian Market</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Wikimedia Commons

Government

Global

KWEB

MCHI

PowerShares Golden Dragon Halter USX China Portfolio

Texas Governor Mandates State Agencies To Divest From China: 'Will Defend And Safeguard Itself...From Any Potential Threat'

Needham analyst Quinn Bolton maintains Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) with a Buy and lowers the price target from $950 to $600.

Price Target

MPWR

Needham Maintains Buy on Monolithic Power Systems, Lowers Price Target to $600

Macro Economic Events

Econ #s

Economics

U.K. Services Purchasing Managers Index Preliminary For November 50.0 Vs. 52.3 Est.; 52.0 Prior

U.K. Manufacturing Purchasing Managers Index Preliminary For November 48.6 Vs. 50.1 Est.; 49.9 Prior

U.K. Composite Purchasing Managers' Index Preliminary For November 49.9 Vs. 51.8 Prior

Eurozone Services Purchasing Managers Index Preliminary For November 49.2 Vs. 51.6 Est.; 51.6 Prior

HCOB Eurozone Composite Purchasing Managers Index Preliminary For November 48.1 Vs. 50.0 Prior

Eurozone Manufacturing Purchasing Managers Index Preliminary For November 45.2 Vs. 46.0 Est.; 46.0 Prior

HC Wainwright &amp; Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRTS#NASDAQ">DRTS</a>) with a Buy and maintains $9 price target.

Reiteration

DRTS

HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target

RBC Capital analyst Deane Dray upgrades Flowserve (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>) from Sector Perform to Outperform and announces $69 price target.

Upgrades

RBC Capital Upgrades Flowserve to Outperform, Announces $69 Price Target

EHang Holdings Limited ("EHang" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>), the world's leading Urban Air Mobility ("UAM") technology platform company, today announced that the Company's Board of Directors has approved a Share Repurchase Program, pursuant to which the Company may repurchase up to&nbsp;US$30&nbsp;million of its American Depositary Shares ("ADSs") or ordinary shares over the next 12 months.

Buybacks

EHang Holdings' Board Approved A Share Buyback Program Of Up To $30M ADSs Over Next 12 Months

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIO#NASDAQ">XBIO</a>) with a Neutral.

XBIO

HC Wainwright & Co. Reiterates Neutral on Xenetic Biosciences

HC Wainwright &amp; Co. analyst Oren Livnat reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $200 price target.

JAZZ

HC Wainwright & Co. Reiterates Buy on Jazz Pharmaceuticals, Maintains $200 Price Target

Piper Sandler analyst Arvind Ramnani maintains Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) with a Overweight and lowers the price target from $768 to $765.

INTU

Piper Sandler Maintains Overweight on Intuit, Lowers Price Target to $765

PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) today announced its agreement to acquire the remaining 50% interest in Sabra Dipping Company, LLC (Sabra) and PepsiCo-Strauss Fresh Dips &amp; Spreads International GmbH (Obela) and become the sole owner of these companies, which make Sabra and Obela products.
&nbsp;
Sabra and Obela are currently 50/50 joint ventures that had been formed between PepsiCo and Strauss Group to manufacture, distribute, and sell refrigerated dips and spreads. The Sabra joint venture is based in New York and operates in the U.S. and Canada. The Obela joint venture is based in Geneva and operates in Australia, New Zealand and Mexico.
PepsiCo has focused on the fresh dips category for over 15 years, forming Sabra and Obela as 50/50 joint ventures with the Strauss Group in 2008 and 2012, respectively. Sabra has become a leading hummus brand with nearly $400MM in retail sales in the U.S. This transaction will enable PepsiCo to continue to transform its portfolio and drive accelerated innovation to develop more products that meet the growing demand for positive choices from North American consumers.

PepsiCo Secures Full Ownership of Sabra and Obela with 50% Buyout

Piper Sandler analyst Brent Bracelin maintains Procore Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) with a Overweight and raises the price target from $70 to $90.

PCOR

Piper Sandler Maintains Overweight on Procore Technologies, Raises Price Target to $90

Shares of Reddit Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) nosedived by 6.2% to $148.11 per share in premarket, despite closing 16% higher at $158.02 apiece on Thursday. Technical analysis points towards a bullish trend, with the stock trading at overbought levels.
What Happened: Reddit&#8217;s shareholder, Advance Magazine Publishers Inc. plans to sell as much as $1.2 billion of the company&#8217;s stake, <a href="https://www.bloomberg.com/news/articles/2024-11-21/advance-magazine-said-to-seek-1-2-billion-in-reddit-share-sale">reported</a> Bloomberg on Friday morning. The company is said to be offering 7.8 million shares in between the range of $145.38-$148.54 each.
Advance Magazine Publishers is an arm of the Newhouse family publishing empire that owns Conde Nast. The company seeks to establish a credit facility using Reddit&#8217;s stake, while buying derivatives on Reddit&#8217;s shares, which allow it to indirectly maintain an ownership stake, reported Bloomberg.
Apart from this, Reddit faced an outage <a href="https://www.benzinga.com/24/11/42118134/reddit-resolves-another-outage-after-morning-disruptions-impact-72000-users">on Wednesday and Thursday</a> this week. This outage stems from an HTTP error, as per TechCrunch. The platform was able to resolve the issue later.
Also read: <a href="https://www.benzinga.com/24/11/42118134/reddit-resolves-another-outage-after-morning-disruptions-impact-72000-users">Reddit Suffers Second Disruption In Two Days</a>
Why It Matters: Technical analysis points towards strong support for the RDDT stock.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="276" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22033719/Reddit-Technical-final-1024x276.png" alt="" class="wp-image-660516" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22033719/Reddit-Technical-final-1024x276.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22033719/Reddit-Technical-final-300x81.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22033719/Reddit-Technical-final-768x207.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22033719/Reddit-Technical-final-1536x414.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22033719/Reddit-Technical-final.png 1737w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Thursday&#8217;s closing price of $158.02 sits above its eight, 20, and 50-day simple moving averages, signaling a bullish trend. However, the stock's distance from its 100-day moving average of $75.59 suggests potential selling opportunities with the relative strength index of 79.18 indicating overbought conditions.
While RDDT stock could face volatility, if the stake sale report holds true its recent upgrade from Piper Sandler citing strong user growth metrics, makes it attractive in the longer term.
According to <a href="https://www.benzinga.com/quote/RDDT/analyst-ratings">Benzinga pro data</a>, Reddit has a consensus price target of $92.84 based on the ratings of 19 analysts. The high is $150 per share issued by Piper Sandler on Nov. 19 and the low is $54 apiece issued by New Street Research on March 26, 2024.
The average price target of $118.33 between Piper Sandler, Bernstein, and Citigroup implies a 19.28% downside for Reddit.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="374" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22033546/reddit-analyst-ratings-1024x374.png" alt="" class="wp-image-660511" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22033546/reddit-analyst-ratings-1024x374.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22033546/reddit-analyst-ratings-300x110.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22033546/reddit-analyst-ratings-768x280.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22033546/reddit-analyst-ratings.png 1071w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read next: <a href="https://www.benzinga.com/24/11/42131911/donald-trump-appointed-doge-to-have-marginal-impact-saving-50-100-billion-says-analyst-as-elon-musk-aims-to-target-500-billion-plus-in-federal-expenditures">Donald Trump&#8217;s DOGE Initiative To Have &#8216;Marginal Impact&#8217; Says Analyst As Elon Musk Aims To Target Over $500B In Federal Expenditures</a>
Image via Shutterstock

Equities

Tech

RDDT

Reddit Tumbles 7% In Premarket Amid Advance's Stake Sale Announcement: Technicals Show Strong Support, But Selling Pressure Persists At Overbought Levels

Piper Sandler analyst Arvind Ramnani assumes PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a Neutral rating and announces Price Target of $88.

Initiation

PYPL

Piper Sandler Assumes PayPal Holdings at Neutral, Announces Price Target of $88

Vivani Medical GAAP EPS of -$0.10 beats by $0.02

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Vivani Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/vani-stock-quote/">VANI</a>) just reported results for the second quarter of 2024.<ul><li>Vivani Medical reported earnings per share of -10 cents. This was above the analyst estimate for EPS of -12 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/vani-stock-earnings-vivani-medical-for-q2-of-2024/">VANI Stock Earnings: Vivani Medical Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VANI Stock Earnings: Vivani Medical Beats EPS for Q2 2024

Naz Rahman, an analyst from Maxim Group, has initiated a new Buy rating on Vivani Medical (VANI). Naz Rahman has given his Buy rating due to a comb...

Innovative Obesity Treatment Promises High Compliance: Buy Recommendation for Vivani Medical

Maxim Group analyst Naz Rahman reiterated a Buy rating on Vivani Medical (VANI – Research Report) yesterday and set a price target of $8.00. Naz Ra...

Buy Rating Affirmed for Vivani Medical on Strong Potential of NPM-115 Implant for Metabolic Disease Treatment

Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Vivani Medical (VANI – Research Report) and keeping the price target at $8.00. Naz R...

Buy Rating on Vivani Medical: Advancing GLP-1 Therapies with Innovative Implantable Treatment

Catalyst Watch: Netflix earnings, Lenovo tech event, Paris Motor Show, and eyes on oil

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

JPMorgan, Five Below downgraded: Wall Street's top analyst calls

Vivani Medical GAAP EPS of -$0.11

Vivani Medical, Inc. ( ($VANI) ) has released its Q3 earnings. Here is a breakdown of the information Vivani Medical, Inc. presented to its investo...

Vivani Medical Reports Q3 Loss, Advances GLP-1 Trials

Vivani Medical Gains 'Buy' Rating Due to Strategic Advancements and Financial Strength

ADBE

ALGM

ALLY

AVDX

BLNK

BYDDF

CAPR

CROX

CTRI

CYTK

DLTR

FIVE

HUBS

IBTA

INTC

LNVGY

MIRM

MSFT

MTEN

NAPA

NFLX

NRBO

NVDA

NVNO

OCGN

OKTA

QCOM

SCHW

SERV

SFHG

SRPT

SRRK

TSLA

ULTA

USGO

VLKAF

VRSSF

ZYME

Press Releases

Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant

Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024

Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now

Presenting on the Emerging Growth Conference 75 Day 2 on September 26

Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024

Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now

Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now

Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results

Comments

Vivani Medical

Vivani Medical (VANI) Opzioni

Vivani Medical (NASDAQ:VANI) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO